Forbidden and Permitted Statements about Medications — Loosening the Rules
- 3 September 2015
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 373 (10), 967-973
- https://doi.org/10.1056/nejmhle1506365
Abstract
The authors discuss recent legal challenges to the authority of the Food and Drug Administration to regulate drug makers' statements about the efficacy and safety of their products.Keywords
This publication has 23 references indexed in Scilit:
- Fungal Infections Associated with Contaminated Methylprednisolone InjectionsThe New England Journal of Medicine, 2013
- Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12.American Journal of Health-System Pharmacy, 2013
- FDA Regulation of Off-label Drug Promotion Under AttackJAMA, 2013
- Drug, Patient, and Physician Characteristics Associated With Off-label Prescribing in Primary CareArchives of Internal Medicine, 2012
- Off-Label Prescription Advertising, the FDA and the First Amendment: A Study in the Values of Commercial Speech ProtectionAmerican Journal of Law & Medicine, 2011
- Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower ComplaintsPLoS Medicine, 2011
- Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialThe Lancet, 2009
- Shifting Terrain in the Regulation of Off-Label Promotion of PharmaceuticalsThe New England Journal of Medicine, 2009
- Off-label Prescribing Among Office-Based PhysiciansArchives of Internal Medicine, 2006
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999